19193-Lung Cancer-NA-632

Lung Cancer

A Phase III, Randomized, Double-Blind, Placebo-controlled study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-Tigit Antibody) in patients with untreated extensive-stage small cell lung cancer (GO41767)

  • Details

ClinicalTrials.gov ID: NCT04256421
Diagnosis Type: NA
USOR Number:

  • Address


Search by practice name, trial titles, indicators and specific disease types.